These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 6523767)

  • 1. [Importance of prognostic indicators in multiple myeloma. II. Selected hematologic indicators].
    Scudla V; Wiedermann B; Wiedermann D; Indrák K; Spidlová A
    Vnitr Lek; 1984 Dec; 30(12):1156-65. PubMed ID: 6523767
    [No Abstract]   [Full Text] [Related]  

  • 2. [The bromodeoxyuridine index in multiple myeloma. I. Relation with selected laboratory indicators of the disease].
    Scudla V; Ordeltová M; Bacovský J; Spidlová A; Budíková M; Kubalová D; Zivná J
    Vnitr Lek; 1996 Jul; 42(7):458-62. PubMed ID: 8928421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of prognostic indicators in multiple myeloma. I. Clinical, biochemical and radiographic indicators].
    Scudla V; Wiedermann B; Wiedermann D; Indrák K
    Vnitr Lek; 1984 Dec; 30(12):1145-55. PubMed ID: 6523766
    [No Abstract]   [Full Text] [Related]  

  • 4. [Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease].
    Scudla V; Bacovský J; Budíková M; Klímová D; Faltýnek L
    Vnitr Lek; 1995 Sep; 41(9):593-8. PubMed ID: 7483349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
    Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
    Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
    Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic and prognostic significance of blood-serum ceruloplasmin, acetylcholinesterase and total proteolytic activity in patients with multiple myeloma].
    Bessmel'tsev SS; Rybakova LP; Gritskevich NL; Golota GZ; Blinov MN; Abdulkadyrov KM
    Vopr Onkol; 1999; 45(4):398-404. PubMed ID: 10532099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
    Abdulkadyrov KM; Stel'mashenko LV; Bessmel'tsev SS; Lubo-Lesnichenko IF; Sel'tser AV; Rozanova OE; Gubarenko NK; Bubnova LN; Mnuskina MM; Zhuchikhina AA; Blinov MN; Gritskevich NL
    Vopr Onkol; 1998; 44(3):304-9. PubMed ID: 9695777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
    Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
    Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
    Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
    Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study on chemotherapy for multiple myeloma. Part III: The disappearance of M-protein in multiple myeloma].
    Adachi T; Hasegawa M; Asano K; Sezaki T; Ishii H; Takahashi I; Kimura I
    Rinsho Ketsueki; 1983 Apr; 24(4):440-7. PubMed ID: 6887544
    [No Abstract]   [Full Text] [Related]  

  • 13. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].
    Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K
    Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
    Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
    Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P; Collacciani A; Maccarone C; Casale R
    Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes of serum interleukin 2 and soluble interleukin 2 receptor and their clinical significance in multiple myeloma].
    Wang Z; Li D; Yang J
    Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):439-41. PubMed ID: 9387297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABO discrepancy in a multiple myeloma patient: a case study.
    Wilson JA; Jacobs A
    Clin Lab Sci; 2002; 15(4):204-7. PubMed ID: 12776779
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic indicators for the diagnosis of multiple myeloma.
    Greipp P;
    Oncology (Williston Park); 2004 May; 18(5):558-60. PubMed ID: 15209186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relation of the soluble cytoadhesion molecules VCAM-1 and ICAM-1 to selected clinical and laboratory indicators in multiple myeloma].
    Scudla V; Budíková M; Bacovský J; Ordeltová M; Opíchalová D; Heincová V
    Vnitr Lek; 1999 Oct; 45(10):583-90. PubMed ID: 10951865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical features and status in multiple myeloma].
    Sawamura M; Murakami H; Ogawara H; Tsuchiya J
    Rinsho Ketsueki; 1993 Apr; 34(4):444-9. PubMed ID: 8510331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.